R
ReCor Medical
A medical device company specialized in the treatment of hypertension
About ReCor Medical
ReCor Medical is a pioneering company in the healthcare sector, specifically targeting the treatment of hypertension, a condition affecting over 1 billion people worldwide. The company has developed a unique therapeutic system known as the Paradise System, which uses non-focused ultrasound technology to perform renal denervation. This innovative approach aims to reduce high blood pressure by targeting the nerves in the kidneys, which play a crucial role in regulating blood pressure.
ReCor Medical primarily serves patients suffering from hypertension, particularly those who have not responded well to traditional antihypertensive medications. The company operates in the global healthcare market, with a strong focus on clinical research and development to validate the effectiveness and safety of its technology.
The business model of ReCor Medical revolves around the development, clinical testing, and commercialization of its renal denervation system. The company generates revenue through the sale of its medical devices and potentially through partnerships with healthcare providers and institutions. Additionally, ReCor Medical is actively involved in clinical trials, such as the RADIANCE Global Program, which is an international, multicenter initiative designed to explore the benefits of renal denervation in treating hypertension. These trials are crucial for gaining regulatory approvals and demonstrating the efficacy of their technology to the medical community.
In summary, ReCor Medical is at the forefront of innovative hypertension treatment, leveraging advanced ultrasound technology to offer a new solution for patients with high blood pressure. The company's commitment to rigorous clinical research and its focus on a significant global health issue position it as a key player in the medical device industry.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jul 2018 | $0 | — | Otsuka Pharmaceutical | ↗ |
| DEBT✓Debt | Jun 2016 | $10M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for ReCor Medical is 5.9K monthly website visits, up 7.3% over the last three months. ReCor Medical's team grew 136.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
ReCor Medical in the Palo Alto ecosystem
The ReCor Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Otsuka Pharmaceutical
Sofinnova Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ReCor Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ReCor Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










